The specter of generic rivalry has repeatedly loomed around copyright’s iconic drug, Sildenafil, sparking questions about the outlook of similar drug stakes. While initial periods saw significant profits, the intellectual property expiration has opened the way for less expensive alternatives, likely diminishing revenue and creating a real hazard